Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has received a consensus rating of "Buy" from the sixteen analysts that are currently covering the stock, Marketbeat Ratings reports. Fifteen analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $172.33.
Several research firms have issued reports on AXSM. Oppenheimer began coverage on shares of Axsome Therapeutics in a research report on Tuesday, June 3rd. They issued an "outperform" rating and a $185.00 price target on the stock. Morgan Stanley began coverage on shares of Axsome Therapeutics in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $190.00 price target on the stock. Royal Bank Of Canada decreased their price target on shares of Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating on the stock in a research report on Thursday, June 12th. Mizuho lifted their price target on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a research report on Thursday, March 27th. Finally, Robert W. Baird lifted their price target on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 6th.
View Our Latest Stock Report on AXSM
Axsome Therapeutics Price Performance
Shares of NASDAQ AXSM traded up $3.94 during mid-day trading on Wednesday, reaching $112.35. 886,827 shares of the company traded hands, compared to its average volume of 668,535. Axsome Therapeutics has a fifty-two week low of $72.21 and a fifty-two week high of $139.13. The company has a debt-to-equity ratio of 3.48, a current ratio of 2.03 and a quick ratio of 1.96. The firm has a market cap of $5.53 billion, a PE ratio of -19.47 and a beta of 0.46. The stock has a fifty day simple moving average of $106.61 and a 200-day simple moving average of $107.92.
Insider Buying and Selling at Axsome Therapeutics
In other Axsome Therapeutics news, Director Mark Coleman sold 3,750 shares of Axsome Therapeutics stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total transaction of $395,512.50. Following the completion of the sale, the director owned 50,387 shares of the company's stock, valued at $5,314,316.89. This trade represents a 6.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel Hunter R. Murdock sold 6,014 shares of Axsome Therapeutics stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $100.12, for a total transaction of $602,121.68. The disclosure for this sale can be found here. Insiders sold 93,437 shares of company stock valued at $9,834,215 in the last quarter. Company insiders own 22.40% of the company's stock.
Institutional Investors Weigh In On Axsome Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of AXSM. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Axsome Therapeutics in the 1st quarter valued at $25,000. NBC Securities Inc. acquired a new stake in shares of Axsome Therapeutics in the 1st quarter valued at $31,000. Quantbot Technologies LP acquired a new stake in shares of Axsome Therapeutics in the 1st quarter valued at $31,000. AlphaQuest LLC bought a new position in Axsome Therapeutics in the 1st quarter worth $38,000. Finally, Neo Ivy Capital Management bought a new position in Axsome Therapeutics in the 1st quarter worth $41,000. Institutional investors and hedge funds own 81.49% of the company's stock.
Axsome Therapeutics Company Profile
(
Get Free ReportAxsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading

Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.